$117.570
+5.926 (+5.04%)Al cierre
Comparativa sectorial de MNPR
In the context of the broader market, MNPR competes directly with industry leaders such as AURA and NGNE. With a market capitalization of $789.15M, it holds a leading position in the sector. When comparing efficiency, MNPR's gross margin of N/A stands against AURA's N/A and NGNE's N/A. Such benchmarking helps identify whether Monopar Therapeutics Inc. is trading at a premium or discount relative to its financial performance.
Desempeño financiero de Monopar Therapeutics Inc
The company has faced significant net losses, with Q2 2026 net income at -5,313,300 USD, but it has shown a positive EPS of 0.62 in Q2 2026, indicating potential recovery.
Financials
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.